Prospective evaluation of fluorescence-in situ-hybridization to detect bladder cancer: results from the UroScreen-Study.

Background: UroScreen is a prospective study for early diagnosis of bladder cancer (BC) in chemical workers formerly exposed to aromatic amines, aimed to assess the performance of molecular tumor markers in comparison with urinary cytology. Here we evaluate the cancer-predictive values and potential effect modifiers of fluorescence-in-situ-hybridization (FISH).

Subjects And Methods: A FISH test was performed in 7,091 urine samples from 1,609 subjects between 2007 and 2010.

Nuclear matrix protein-22: a prospective evaluation in a population at risk for bladder cancer. Results from the UroScreen study.

Unlabelled: What's known on the subject? and What does the study add? The prognosis of bladder cancer significantly depends on tumour stage and time of diagnosis so early diagnosis is desirable to decrease mortality and treatment costs. The NMP22 test is approved for clinical application by the Food and Drug Administration (FDA) of the US. Previous studies have reported values of 47-100% for sensitivity and 58-91% for specificity with this test, but there is no new data on the predictive value of NMP22 for screening bladder cancer (BC).

The role of haematuria in bladder cancer screening among men with former occupational exposure to aromatic amines.

Unlabelled: Study Type - Diagnostic (validating cohort).

Level Of Evidence: 1b. What's known on the subject? and What does the study add? Microscopic haematuria (µH) is frequently detected in elderly adults.